We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-5.72%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$322M
AUM Growth
-$34.8M
Cap. Flow
-$3.33M
Cap. Flow %
-1.03%
Top 10 Hldgs %
62.73%
Holding
76
New
14
Increased
20
Reduced
18
Closed
19
Avg Time Held Equity + Options
0.7 years
Top 10 Avg Time Held Equity + Options
0.8 years
Top 20 Avg Time Held Equity + Options
0.8 years
Avg Time Held Equity only
0.8 years
Top 10 Avg Time Held Equity only
0.8 years
Top 20 Avg Time Held Equity only
0.8 years

Top Buys

Rank Stock Value
1
ENSG icon
The Ensign Group
ENSG
+$14.9M
2
GSK icon
GSK
GSK
+$11.9M
3
ASND icon
Ascendis Pharma A/S
ASND
+$11.2M
4
NVST icon
Envista
NVST
+$8.88M
5
DXCM icon
DexCom
DXCM
+$6.92M

Top Sells

Rank Stock Value
1
RCM icon
R1 RCM Inc. Common Stock
RCM
+$23.3M
2
EHTH icon
eHealth
EHTH
+$12.3M
3
RDUS icon
Radius Health, Inc.
RDUS
+$8.96M
4
DCPH icon
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$8.38M
5
NUVA
NuVasive, Inc.
NUVA
+$5.37M

Sector Composition

Rank Sector Weight
1 Healthcare 90.47%
2 Real Estate 4.59%
3 Industrials 2.01%
4 Communication Services 1.04%
5 Miscellaneous 1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
LUMO icon
51
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$434K 0.13%
+30,331
New +$445K
2019 Q3
0 quarters
PFNX
52
DELISTED
Pfenex Inc.
PFNX
$405K 0.13%
47,968
-33,000
-41% -$239K
2019 Q1
2 quarters
CVM icon
53
PUT
CEL-SCI Corp
CVM
$31.1M
$383K 0.12%
+1,427
New +$334K
2019 Q3
0 quarters
ALBO
54
DELISTED
Albireo Pharma Inc
ALBO
$361K 0.11%
18,029
– –
2018 Q1
6 quarters
AIMT
55
PUT
DELISTED
Aimmune Therapeutics
AIMT
$209K 0.07%
+10,000
New +$204K
2019 Q3
0 quarters
AIMT
56
CALL
DELISTED
Aimmune Therapeutics
AIMT
$191K 0.06%
+9,100
New +$186K
2019 Q3
0 quarters
AKRX
57
DELISTED
Akorn Inc
AKRX
$153K 0.05%
40,242
-91,398
-69% -$327K
2019 Q2
1 quarter
BCRX icon
58
CALL
BioCryst Pharmaceuticals
BCRX
$1.98B
– –
-101,800
Closed -$386K –
CNC icon
59
Centene
CNC
$34.3B
– –
-99,600
Closed -$5.22M –
KRSA
60
Korsana Biosciences, Inc. Common Stock
KRSA
$1.49B
– –
-135
Closed -$217K –
ELV icon
61
Elevance Health
ELV
$92.9B
– –
-10,000
Closed -$2.82M –
HUM icon
62
Humana
HUM
$50.1B
– –
-10,000
Closed -$2.66M –
NGNE icon
63
Neurogene
NGNE
$473M
– –
-3,686
Closed -$174K –
PTCT icon
64
PTC Therapeutics
PTCT
$4.95B
– –
-48,600
Closed -$2.19M –
SRPT icon
65
Sarepta Therapeutics
SRPT
$1.81B
– –
-16,554
Closed -$2.52M –
CBAY icon
66
DELISTED
Cymabay Therapeutics
CBAY
– –
-84,296
Closed -$604K –
NUVA
67
DELISTED
NuVasive, Inc.
NUVA
– –
-91,798
Closed -$5.37M –
PRVB
68
DELISTED
Provention Bio, Inc. Common Stock
PRVB
– –
-73,661
Closed -$891K –
ARNA
69
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-73,501
Closed -$4.31M –
MYOK
70
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-56,652
Closed -$2.84M –
FOMX
71
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
– –
-263,390
Closed -$627K –
DERM icon
72
DELISTED
Dermira, Inc.
DERM
– –
-399,874
Closed -$3.82M –
MDCO
73
DELISTED
Medicines Co
MDCO
– –
-57,200
Closed -$2.09M –
GHDX
74
DELISTED
Genomic Health, Inc.
GHDX
– –
-38,403
Closed -$2.23M –
ZGNX
75
CALL
DELISTED
Zogenix, Inc.
ZGNX
– –
-104,300
Closed -$4.98M –
1 2
3
4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q3 2019 Portfolio in Review

As of Q3 2019, Eversept Partners held 76 positions worth $322M, down 9.7% from $357M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Eversept Partners's Q3 2019 filing shows 14 new, 20 increased, 18 reduced and 19 closed positions. Its largest new stake was Envista: 318,000 shares worth $8.87M. The largest sale was R1 RCM Inc. Common Stock, an estimated $23.3M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 82% a quarter earlier, followed by Real Estate and Industrials.

  • Eversept Partners's largest Q3 2019 buy was Envista: 318,000 shares worth $8.87M.
  • Eversept Partners added most to The Ensign Group in Q3 2019, an estimated $14.9M increase.
  • Eversept Partners's biggest Q3 2019 reduction was R1 RCM Inc. Common Stock, cutting an estimated $23.3M.
  • Eversept Partners fully exited NuVasive, Inc. in Q3 2019, selling an estimated $5.37M.
  • Eversept Partners's ten largest holdings make up 63% of its $322M portfolio in Q3 2019.
  • Eversept Partners opened 14 new positions and closed 19 in Q3 2019.
  • Eversept Partners's portfolio value fell 9.7% quarter-over-quarter to $322M.

Based on Eversept Partners's 13F filing for Q3 2019, filed 13 Nov 2019.